Welcome to our dedicated page for Semler Scientific news (Ticker: SMLR), a resource for investors and traders seeking the latest updates and insights on Semler Scientific stock.
Semler Scientific, Inc. (SMLR) combines cutting-edge healthcare diagnostics with innovative financial strategies, making it a unique player in medical technology and digital asset management. This news hub provides investors with essential updates on the company's FDA-cleared QuantaFlo® system and its disciplined bitcoin treasury approach.
Find timely press releases covering regulatory milestones, product developments, earnings reports alongside strategic financial decisions. Our curated collection helps stakeholders track both medical innovations and digital asset performance metrics like BTC Yield - crucial for understanding SMLR's dual-focused value proposition.
Key updates include chronic disease management advancements, cardiovascular diagnostic innovations, and treasury strategy evolution. Bookmark this page for centralized access to SMLR's latest operational developments and financial disclosures, enabling informed analysis of its healthcare technology leadership and digital asset integration.
Semler Scientific announced the purchase of an additional 247 bitcoins for $17 million in cash, including fees and expenses. This brings their total bitcoin holdings to 828, acquired for $57 million. CEO Doug Murphy-Chutorian emphasized their dual strategy of expanding their healthcare business and investing in bitcoin, viewing it as a reliable store of value. As of June 6, 2024, the company continues to focus on these strategies.
Semler Scientific (Nasdaq: SMLR) has adopted bitcoin as its primary treasury reserve asset, purchasing 581 bitcoins for $40 million. Chairman Eric Semler stated that bitcoin's scarcity and digital resilience make it a superior store of value and a potential hedge against inflation compared to gold. The SEC's approval of bitcoin exchange-traded funds and institutional investments validate this strategy. Despite the bitcoin focus, Semler will continue prioritizing its core medical products, particularly QuantaFlo® for peripheral arterial disease testing, while seeking FDA clearance for expanded labeling. Bitcoin holdings will be subject to market conditions and cash needs.
Semler Scientific, Inc. reported $15.9 million in revenue for the first quarter of 2024, a 13% decrease from the same period in 2023. Net income increased by 22% to $6.1 million. The company's cash balance rose to $62.9 million. Despite revenue decline from the PAD product, the CEO remains optimistic about future revenue growth pending FDA clearance for a new product. Semler Scientific also achieved year-over-year net income growth and a record cash balance.
FAQ
What is the current stock price of Semler Scientific (SMLR)?
What is the market cap of Semler Scientific (SMLR)?
